Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
5
×
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
5
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
drugs
startups
deals
europe blog main
europe top stories
investing
merck
otsuka pharmaceutical
roche
venture capital
What
fda
5
×
bio
drug
roundup
approved
cancer
medicine
new
activity
ahead
approvals
asco
biogen
branded
choices
clamped
commissioner
companies
consumers
costly
counterweight
covid
deeper
delays
developing
digital
disease
dna
drugs
economic
eisai
elevatebio
epidemic
fast
fatty
fingerprint
flags
frenzied
generic
genetic
Language
unset
Current search:
cancer
×
fda
×
" raleigh-durham top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
